- Home
- DAL vs MRNA Comparison
DAL vs MRNA Comparison
Compare DAL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAL | MRNA |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | United States |
| Employees | 78400 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9B | 61.6B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DAL | MRNA |
|---|---|---|
| Price | $75.47 | $214.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 23 |
| Target Price | $101.07 | ★ $123.61 |
| AVG Volume (30 Days) | 7.3M | ★ 14.8M |
| Earning Date | 10-09-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 43.71 | 21.77 |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $41,244,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $18.26 | $8.09 |
| Revenue Next Year | $3.10 | $16.06 |
| P/E Ratio | $24.79 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $55.03 | $22.28 |
| 52 Week High | $95.68 | $242.29 |
Technical Indicators
Market Signals| Indicator | DAL | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 60.63 |
| Support Level | $64.41 | $45.39 |
| Resistance Level | $85.02 | N/A |
| Average True Range (ATR) | 2.25 | 16.26 |
| MACD | -0.80 | 0.12 |
| Stochastic Oscillator | 2.76 | 51.15 |
Price Performance
Historical ComparisonAbout DAL Delta Air Lines Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.